Skip to main content
SpringerLink
Log in

Enzalutamide delays pain progression in prostate cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded and treatment supplied by Astellas Pharma Inc and Medivation LLC, a Pfizer Company.

Reference

  • Tombal B, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology : 12 Feb 2019. Available from: URL: https://doi.org/10.1016/S1470-2045(18)30898-2

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Enzalutamide delays pain progression in prostate cancer. PharmacoEcon Outcomes News 822, 8 (2019). https://doi.org/10.1007/s40274-019-5660-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5660-9

Search

Navigation